Monte Rosa Therapeutics, Inc. (GLUE) — Operating Income
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$54.21M | +33.2% |
| 2024 | -$81.11M | +43.4% |
| 2023 | -$143.31M | -27.5% |
| 2022 | -$112.38M | -54.2% |
| 2021 | -$72.88M | -160.2% |
| 2020 | -$28.01M | — |
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$54.21M | +33.2% |
| 2024 | -$81.11M | +43.4% |
| 2023 | -$143.31M | -27.5% |
| 2022 | -$112.38M | -54.2% |
| 2021 | -$72.88M | -160.2% |
| 2020 | -$28.01M | — |